Drugs / TRICAR-ALL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05010564 | Jul 2023 → Jul 2026 overdue | B-cell acute lymphoblastic leukemia | Baylor College of Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRICAR-ALL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05010564 ↗ |
| Route | Intravenous | “An injection of TRICAR-ALL T-cells will be given into a vein through an IV at the assigned dose.” NCT05010564 ↗ |